Yu-Wen Hu

Yu-Wen Hu

Auto-generated profile, based on publicly available information

Yu-Wen Hu

Department of Heavy Particles and Radiation Oncology, Taipei Veterans General Hospital, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2015 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
PDF file
CTChung-Jen Teng
Chung-Jen Teng
YHYu-Wen Hu
Yu-Wen Hu
SCSan-Chi Chen
San-Chi Chen
CYChiu-Mei Yeh
Chiu-Mei Yeh
HCHuey-Ling Chiang
Huey-Ling Chiang
CLChia-Jen Liu
Chia-Jen Liu
Background: Radioactive iodine (RAI) is widely used for the treatment of thyroid cancers. However, information on associations between RAI dose and second primary malignancy (SPM) is lacking. Methods: Patients without antecedent cancer age 20 years or older and newly diagnosed with thyroid cancer were recruited from the Taiwan National Health Insurance database between 1997 and 2010. Standardized incidence ratios (SIRs) for the cancers were calculated to compare the incidence of thyroid cancer with the general population. The association between RAI dosage and cancer development was estimated using time-dependent Cox regression analysis. All statistical tests were two-sided. Results: A total of 692 cases of SPM were identified among 20 235 patients with thyroid cancer. Regarding the latter, 79.7% of the patients were women, the median age was 46 years, and the follow-up period included 134 178 person-years. The SIR for any SPM was 1.41 (95% confidence interval [CI] = 1.31 to 1.52). A statistically significantly higher SIR was observed in leukemia (2.74), non-Hodgkin’s lymphoma (2.38), prostate (2.30), lung and mediastinum (1.93), pancreas (1.83), kidney (1.81), breast (1.48), and colon-rectum (1.31) cancers. Cumulative RAI dose (per 30 mCi increase) conferred a strong risk for SPM (adjusted hazard ratio [aHR] = 1.01, 95% CI = 1.01 to 1.02, P < .001) and leukemia (aHR = 1.03, 95% CI = 1.02 to 1.04, P < .001) occurrences. A cumulative RAI dose greater than 150 mCi possessed a statistically significant risk for all cancer combined (aHR = 1.30) and leukemia (aHR = 6.03). Conclusions: An increased risk of SPM was observed for thyroid cancer patients, especially with cumulative RAI doses over 150 mCi.

28 March 2017 in Head & Neck
Verified
Journal Article
Closed access
PDF file
TWTi-Hao Wang
Ti-Hao Wang
CLChia‐Jen Liu
Chia‐Jen Liu
TCTze‐Fan Chao
Tze‐Fan Chao
TCTzeng‐Ji Chen
Tzeng‐Ji Chen
YHYu‐Wen Hu
Yu‐Wen Hu

17 March 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NHNing Hung
Ning Hung
CSCheng Che Shen
Cheng Che Shen
YHYu-Wen Hu
Yu-Wen Hu
LHLi-Yu Hu
Li-Yu Hu
CYChiu-Mei Yeh
Chiu-Mei Yeh
CLChia-Jen Liu
Chia-Jen Liu
This study evaluated the risk of cancer among patients with iron deficiency anemia (IDA) by using a nationwide population-based data set. Patients newly diagnosed with IDA and without antecedent cancer between 2000 and 2010 were recruited from the Taiwan National Health Insurance Research Database. The standardized incidence ratios (SIRs) of cancer types among patients with IDA were calculated. Patients with IDA exhibited an increased overall cancer risk (SIR: 2.15). Subgroup analysis showed that patients of both sexes and in all age groups had an increased SIR. After we excluded patients diagnosed with cancer within the first and first 5 years of IDA diagnosis, the SIRs remained significantly elevated at 1.43 and 1.30, respectively. In addition, the risks of pancreatic (SIR: 2.31), kidney (SIR: 2.23), liver (SIR: 1.94), and bladder cancers (SIR: 1.74) remained significantly increased after exclusion of patients diagnosed with cancer within 5 years after IDA diagnosis. The overall cancer risk was significantly elevated among patients with IDA. After we excluded patients diagnosed with IDA and cancer within 1 and 5 years, the SIRs remained significantly elevated compared with those of the general population. The increased risk of cancer was not confined to gastrointestinal cancer when the SIRs of pancreatic, kidney, liver, and bladder cancers significantly increased after exclusion of patients diagnosed with IDA and cancer within the first 5 years. This finding may be caused by immune activities altered by IDA. Further study is necessary to determine the association between IDA and cancer risk.

11 October 2012 in Neuroepidemiology
Verified
Journal Article
Closed access
SOShuo-Ming Ou
Shuo-Ming Ou
YLYi-Jung Lee
Yi-Jung Lee
YHYu-Wen Hu
Yu-Wen Hu
CLChia-Jen Liu
Chia-Jen Liu
TCTzeng-Ji Chen
Tzeng-Ji Chen
SWShuu-Jiun Wang
Shuu-Jiun Wang
Background: Previous studies suggested a decreased risk of cancer among patients with Alzheimer’s disease (AD). There is still a lack of data on the specific types of cancer, the risk factors, and the impact of cholinesterase inhibitors on developing cancer in AD. Methods: We performed a nationwide population-based study of 6,960 patients with AD between 1997 and 2006 using Taiwan’s National Health Insurance database. Patterns of cancer incidence in AD patients were compared with those of the general population using standardized incidence ratios (SIRs). Results: Patients with AD had a reduced risk of developing overall cancer [SIR = 0.88, 95% confidence interval (CI) = 0.80–0.97]. Specifically, patients with AD were protected from lung cancers (SIR = 0.75, 95% CI = 0.57–0.98), especially men (SIR = 0.61, 95% CI = 0.40–0.88). In subgroup analyses, women, patients aged 60–79 years, and those diagnosed as having AD for more than 1 year were more likely to be protected from cancers. Conclusions: Our study demonstrates a decreased incidence of overall cancers in patients with AD, a finding lower than but consistent with Western countries. Patients with AD had a significantly decreased risk of lung cancer. Further investigation of genetic evidence linking AD to cancer is warranted.

17 April 2015 in Cancer
Verified
Journal Article
Open access
PDF file
CLChia‐Jen Liu
Chia‐Jen Liu
YCYiing‐Jenq Chou
Yiing‐Jenq Chou
CTChung‐Jen Teng
Chung‐Jen Teng
CLChun‐Chi Lin
Chun‐Chi Lin
YLYu‐Ting Lee
Yu‐Ting Lee
NHNicole Huang
Nicole Huang
BACKGROUND: Patients with colorectal cancer (CRC) who undergo cancer surgeries with higher‐volume providers may have better outcomes. The current debate focuses on whether it is hospital volume or surgeon volume that matters more.METHODS: The authors conducted a nationwide population‐based study in Taiwan that enrolled all patients who underwent definitive surgery for newly diagnosed CRC between 2005 and 2011. All patients were divided into 4 quartiles according to hospital and surgeon volume. The main outcome was the 5‐year mortality rate, which was analyzed using a frailty model for Cox regression. The authors also conducted fixed and random effects multivariate regression models to examine short‐term outcomes and resource use, including operative mortality, hospital stay, emergency department visits within 30 days, and medical expenses. Analyses were adjusted for patient and provider characteristics.RESULTS: A total of 61,728 patients with CRC were included in the current study. The 5‐year mortality rates were 38.7%, 32.8%, 32.0%, and 29.1% in descending order of hospital volume quartiles and were 41.4%, 34.1%, 29.8%, and 27.4% in descending order of surgeon volume quartiles. After adjustment for the individual and provider characteristics, surgeon volume, but not hospital volume, remained a significantly predictive factor of death (P<.001). In addition, those patients with CRC who underwent definitive surgeries performed by higher‐volume surgeons had a relatively lower risk of operative mortality, shorter hospital length of stay, and lower medical expenses.CONCLUSIONS: Patients with CRC who underwent definitive surgery performed by higher‐volume providers were found to have better outcomes. Surgeon volume may play a more important role than hospital volume. Cancer 2015;121:2782‐2790. © 2015 American Cancer Society

1 February 2015 in The Journal of Pediatrics
Verified
Journal Article
Closed access
HCHuey-Ling Chiang
Huey-Ling Chiang
CLChia-Jen Liu
Chia-Jen Liu
YHYu-Wen Hu
Yu-Wen Hu
SCSan-Chi Chen
San-Chi Chen
LHLi-Yu Hu
Li-Yu Hu
SGSusan Shurfen Gau
Susan Shurfen Gau